Drägerwerk stock holds strong gains as SDAX performer

Published on 09/21/2026 at 17:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Drägerwerk stock closed at 114.00 EUR on Xetra on September 18, 2026, almost 49 percent above its level a year earlier. The medical and safety technology group recently reported higher revenue and earnings for the first half of 2026.

Moderne Intensivstation mit Beatmungsgerät und Patientenmonitoring in klinischer Umgebung — Drägerwerk AG & Co. KGaA zeigt moderne Intensivstation mit Beatmungsgeräten und Patientenmonitoring DE0005550636, Illustration mit AI erstellt.

Drägerwerk stock (ISIN DE0005550636) finished the most recent completed Xetra session at 114.00 EUR on September 18, 2026, placing the German medical and safety technology specialist among the stronger performers in the SDAX over the past year. As of the first half of 2026, the company reported higher revenue and improved earnings compared with the prior-year period, underlining the operating backdrop for the latest share price level.

Share price performance and SDAX context

According to finanzen.net, Drägerwerk stock closed the Xetra session on September 18, 2026 at 114.00 EUR, down 1.00 EUR or 0.87 percent from the previous close of 115.00 EUR, with an intraday range between 114.00 EUR and 116.60 EUR. In the same overview, the stock is shown with a 12-month performance of 48.50 percent, highlighting how much Drägerwerk has outpaced many SDAX peers over the past year.

A separate performance analysis from finanzen.ch on September 21, 2026 illustrates the long-term move: an investor who put 100 EUR into Drägerwerk shares at a price of 44.65 EUR three years earlier would now hold about 2.24 shares worth 255.32 EUR at the September 18, 2026 closing price of 114.00 EUR, corresponding to a gain of 155.32 percent over that period.

Recent earnings trends and operating backdrop

In its most recent half-year report for the first half of 2026, Drägerwerk reported increased revenue compared with the prior-year period, reflecting demand both in medical technology and in safety products; the company also improved earnings, supported by higher volumes and efficiency measures in key segments. According to the financial information made available via the company's investor relations pages at Drägerwerk, revenue in the first half of 2026 exceeded the prior-year level, while operating profit also rose over the same period.

These improvements build on the company's ongoing cost and efficiency programs and a product mix that has shifted toward higher-margin solutions in intensive care and safety systems. In combination with the strong three-year share price performance highlighted by finanzen.ch, the earnings trend suggests that markets are rewarding Drägerwerk for a more robust profitability profile than in earlier years.

Analyst stance and risk considerations

An overview of recent analyst assessments from finanzen.net dated September 21, 2026 shows that houses such as DZ BANK and Jefferies have maintained Hold or equivalent ratings on Drägerwerk during 2026, indicating that despite the strong share-price gains, major analysts see a balanced risk-reward profile rather than a clear valuation mispricing. For investors, this combination of a roughly 48.50 percent one-year gain and predominantly neutral ratings underscores that future performance will likely depend on whether Drägerwerk can sustain revenue growth and margins beyond the current reporting period.

At the same time, the company remains exposed to cyclical swings in hospital and industrial investment cycles, as well as to currency and supply-chain effects, which can influence order intake and profitability from quarter to quarter. The recent share-price strength and the performance metrics cited by finanzen.net and finanzen.ch therefore also imply that the stock could be more sensitive to any disappointment in future quarterly figures.

Drägerwerk stock price snapshot

As of the Xetra close on September 18, 2026, Drägerwerk stock traded at 114.00 EUR, with the latest 52-week performance data from finanzen.net indicating a 48.50 percent gain over the past year and a prior close of 115.00 EUR. Within that 12-month span, the stock has moved between its 52-week low and high in a way that leaves the latest closing price closer to the upper end of the range, underlining that Drägerwerk remains one of the stronger SDAX names from a recent performance perspective.